Interim PET/CT Evaluation in First-Line Follicular Lymphoma
Authors:
- Maria PozaMPMaria Poza
- Alejandro Martin-MuñozAMAlejandro Martin-Muñoz
- Patricia López-PereiraPLPatricia López-Pereira
- Gloria FigaredoGFGloria Figaredo
- Irene ZamanilloIZIrene Zamanillo
- Rodrigo IñiguezRIRodrigo Iñiguez
- Ana Carla OliveiraAOAna Carla Oliveira
- Tycho BaumannTBTycho Baumann
- Antonia Rodriguez-IzquierdoARAntonia Rodriguez-Izquierdo
- Carlos GrandeCGCarlos Grande
- Pilar SarandesesPSPilar Sarandeses
- Enrique RevillaEREnrique Revilla
Preprint
- 29 January 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background/Objectives: This study aimed to determine whether interim PET/CT (iP-ET) scans could identify follicular lymphoma (FL) patients at high risk of relapse fol-lowing first-line therapy. Additionally, the potential of cell-free DNA (cfDNA) analysis to complement iPET in predicting outcomes was explored. Methods: A total of 121 FL patients who underwent iPET scans were included, with responses interpreted using the Deauville score (DS). Progression-free survival (PFS) was evaluated over a median follow-up of 34 months. Interim cfDNA data were analyzed for 14 patients to assess its potential for detecting false-positive PET results. Results: Overall, 34% of patients were classified as iPET(+), with significantly worse estimated 5-year PFS compared to iPET(-) patients (29% vs. 72%, hazard ratio 4.31, p < 0.001). Multivariate analysis confirmed iPET(+) as an independent predictor of PFS. Rituximab maintenance was predictive of reduced progression within the iPET(+) group but not among iPET(-) patients. cfDNA analysis identified two false-positive iPET cases and showed potential to identify pa-tients with complete response at risk of early progression. Conclusions: Interim PET results are significant predictors of PFS in FL first-line therapy and could inform re-sponse-adapted treatment strategies. cfDNA analysis has the potential to complement PET/CT by improving specificity and identifying patients at risk of early progression, offering a more precise approach to managing FL.Keywords
All Related Versions
- Version 1, 2025-01-29, Preprints
- Published version: Cancers, 17 (7), 1065.
This publication has 46 references indexed in Scilit:
- Impact of rituximab on COVID-19 outcomesAnnals of Hematology, 2021
- Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure after frontline immunochemotherapyAmerican Journal of Hematology, 2020
- RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO groupAnnals of Hematology, 2020
- Predictive Value of Interim and End-of-Therapy 18F-FDG PET/CT in Patients with Follicular LymphomaNuclear Medicine and Molecular Imaging, 2019
- NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET‐GUIDED, RESPONSE‐ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED‐STAGE, HIGH‐TUMOUR‐BURDEN FOLLICULAR LYMPHOMAHematological Oncology, 2019
- Progression‐free survival at 2 years post‐autologous transplant: a surrogate end point for overall survival in follicular lymphomaCancer Medicine, 2017
- Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab ExposureTransplantation and Cellular Therapy, 2017
- Pros and cons of rituximab maintenance in follicular lymphomaCancer Treatment Reviews, 2017
- Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapyAnnals of Hematology, 2016
- The prognostic value of mid- and post-treatment [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphomaAnnals of Nuclear Medicine, 2014